Recent questions tagged prescription-drugs

0 votes

0 answers 193 views

CMS Prescription Drug & Health Care Spending data collection -- comments to OMB invited (by 5/30)

asked 7 months ago by Andrew Reamer (58.3k points)

0 votes

0 answers 350 views

CMS Prescription Drug Data from MA–PD, PDP, Fallout Plans/Sponsors for Part D Payments--comments to OMB invited (by 4/4)

asked 9 months ago by Andrew Reamer (58.3k points)

0 votes

0 answers 407 views

FDA Survey on Quantitative Claims in Direct-to-Consumer Prescription Drug Ads -- comments to OMB invited (by 1/22)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 402 views

CMS Prescription Drug Data from MA–PD, PDP, and Fallout Plans/Sponsors for Part D Payments -- comments invited (by 2/16)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 481 views

CMS Survey of Retail [Outpatient Drug] Prices -- comments to OMB invited (by 11/20)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 345 views

FDA Importation of Prescription Drugs data collection -- comments invited to OMB (by 11/20)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 314 views

Drug Price Negotiation Counteroffer -- CMS invites comments to OMB on form (by 8/24)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 366 views

Prescription Drug Data Collection from MA–PD, PDP -- CMS invites comment to OMB (by 8/16)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 453 views

Medicare Drug Price Negotiation Program -- CMS releases revised guidance (6.30.23)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 532 views

Drug Manufacturer IRA Negotiation Data Elements -- CMS invites comments to OMB (by 8/2)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 370 views

Prescription Drug Promotion Research -- FDA invites comments to OMB on proposed tradeoff analysis (by 6/5)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 452 views

Prescription Drug & Health Care Spending -- CMS invites comment on data collection (by 5/26)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 468 views

Medicare Drug Price Negotiation Program -- CMS invites comment on initial guidance (by 4/14)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 371 views

Medicare Prescription Drug Inflation Rebate Program -- CMS seeks input on initial guidance (by 3/11)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 955 views

Dosage/Administration Labeling for Prescription Drugs -- FDA invites comments on draft guidance (by 3/14)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 699 views

Medicare Advantage (MA) Plans & Prescription Drug Plans (PDP) Bid Pricing Tool -- CMS invites comments to OMB (by 2/13)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 425 views

Medicare Drug Price Negotiation Program -- CMS Announces Key Y1 Dates (1.11.23)

asked 1 year ago by Andrew Reamer (58.3k points)

0 votes

0 answers 1.2k views

CMS 2024 Proposed Changes to Medicare Advantage/Medicare Part D Programs--comments invited (by 2/13)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 1.2k views

Prescription Drug Prices 2016-2022 and Spending 2016-2021 -- ASPE reports (9.30.22)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 607 views

Intl Prescription Drug Price Comparisons: Current Empirical Estimates/Comparisons w/ Previous Studies -- ASPE (7.1.22)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 1.3k views

Prescription Drug/Health Care Spending Data Collection (RxDC) -- CMS invites comments to OMB (by 7/28)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 539 views

Prescription Drug Promotion Research -- FDA invites comments on proposed tradeoff analysis (by 6/24)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 841 views

Impact of PBM Business Practices on Drug Affordability/Access -- FTC requests information (by 5/25)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 652 views

Medicare Advantage and Part D Proposed Rule for 2023 -- CMS invites comments (by 3/7)

asked 2 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 534 views

Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships -- ASPE issues RAND report (10/14)

asked 3 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 701 views

Annual Drug/Health Care Spending Data Collection -- CMS/EBSA/IRS/OPM invite comments on interim rule (by 1/24)

asked 3 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 853 views

Enhancing Safety/Security of Pharma Distribution Supply Chain -- FDA public mtg (11/16), seeks comments (by 1/18)

asked 3 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 840 views

Prescription Drug Event (PDE) Data Collection from Part D Providers -- CMS invites comment to OMB (by 10/4)

asked 3 years ago by Andrew Reamer (58.3k points)

0 votes

0 answers 692 views

Prescription Drug Data for Medicare Part D Payments -- CMS invites comments on proposed collection (by 8/23)

asked 3 years ago by Andrew Reamer (58.3k points)